Metastasis remains a critical challenge in cancer treatment and the leading cause of cancer-related mortality. Ongoing research has demonstrated the ...
Metastasis and disease progression remain the leading causes of mortality in both breast and cervical cancer. These processes ...
Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy.
About 10% of acute hepatitis cases and 50% of acute liver failure are caused by drug induction, where treatment remains largely limited. The SLIT/ROBO signaling axis is composed of the secretory SLIT ...
Pitavastatin, a cholesterol lowering drug, slashes chemotherapy resistance in breast cancer by obstructing a specific protein ...
Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS), a clinical-stage radiopharmaceutical company developing first-in-class drug candidate uTREAT® targeting uPAR (urokinase-type plasminogen ...
The dual inhibition of PD-1 and VEGF pathways by ivonescimab aims to enhance immune response and limit tumor angiogenesis, ...
How can cannabidiol (CBD) combat cancer tumors? This is what a recent study published in Phytomedicine hopes to address as a ...
The Science, Clinical Promise, & Market OutlookMELBOURNE, Australia, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company ...
Cannabidiol (CBD), a non-intoxicating compound in marijuana, “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties, a new scientific review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback